MYC and AL amyloidosis: Our results indicate that proteasome inhibitors are potent antagonists of the c-MYC regulon, highlight the transcriptional dynamics between gene activators and repressors in multiple myeloma, and open potential avenues for personalized treatment options involving epigenetic modifiers.